Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 0.71 |
| ▸ | HPGD | P15428 | 3/20 | 0.67 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.67 |
| ▸ | GAA | P10253 | 1/20 | 0.67 |
| ▸ | RECQL | P46063 | 1/20 | 0.66 |
| ▸ | LMNA | P02545 | 2/20 | 0.63 |
| ▸ | ACACB | O00763 | 1/20 | 0.61 |
| ▸ | HTT | P42858 | 2/20 | 0.60 |
| ▸ | TSHR | P16473 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6457656 | 1.00 | POLB (0.71) | POLBHPGDSMN1; SMN2GAARECQL | |
| SCHEMBL6922906 | 1.00 | POLB (0.71) | POLBHPGDSMN1; SMN2GAARECQL | |
| SCHEMBL19200906 | 0.92 | ACACB (0.71) | POLBHPGDSMN1; SMN2GAARECQL | |
| SCHEMBL5521105 | 0.86 | POLB (0.73) | POLBHPGDSMN1; SMN2GAARECQL | |
| SCHEMBL516877 | 0.85 | ACACB (0.62) | POLBHPGDSMN1; SMN2GAARECQL | |
| SCHEMBL516876 | 0.85 | ACACB (0.62) | POLBHPGDSMN1; SMN2GAARECQL | |
| SCHEMBL10378902 | 0.85 | POLB (0.71) | POLBHPGDSMN1; SMN2GAARECQL | |
| SCHEMBL10379638 | 0.85 | POLB (0.71) | POLBHPGDSMN1; SMN2GAARECQL | |
| SCHEMBL10671340 | 0.85 | POLB (0.71) | POLBHPGDSMN1; SMN2GAARECQL | |
| SCHEMBL517633 | 0.84 | RECQL (0.91) | POLBHPGDSMN1; SMN2GAARECQL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9789118-B2 | Bicyclic acetyl-CoA carboxylase inhibitors and uses thereof | NOVARTIS AG (CH) | 2017-10-17 | — | — | US | disclosed |
| EP-2598486-B1 | BICYCLIC ACETYL-COA CARBOXYLASE INHIBITORS | NOVARTIS AG (CH) | 2017-06-28 | — | — | EP | disclosed |
| US-8697739-B2 | Bicyclic acetyl-CoA carboxylase inhibitors and uses thereof | NOVARTIS AG (CH) | 2014-04-15 | — | — | US | disclosed |
| EP-2598486-A1 | BICYCLIC ACETYL-COA CARBOXYLASE INHIBITORS | Novartis AG (CH) | 2013-06-05 | — | — | EP | disclosed |
| WO-2012013716-A1 | BICYCLIC ACETYL-COA CARBOXYLASE INHIBITORS | NOVARTIS AG (CH) | 2012-02-02 | — | — | WO | disclosed |
| WO-2012013716-A1 | BICYCLIC ACETYL-COA CARBOXYLASE INHIBITORS | NOVARTIS AG (CH) | 2012-02-02 | — | — | WO | disclosed |
| WO-2011067306-A1 | CYCLOHEXANE DERIVATIVES AS INHIBITORS OF ACETYL-COA CARBOXYLASE (ACC) | NOVARTIS AG (CH) | 2011-06-09 | — | — | WO | disclosed |
| US-20050197350-A1 | Novel quinoline, tetrahydroquinazoline, and pyrimidine derivatives and methods of treatment related to the use thereof | TAISHO PHARMACEUTICAL CO., LTD. | 2005-09-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050197350-A1 | Novel quinoline, tetrahydroquinazoline, and pyrimidine derivatives and methods of treatment related to the use thereof | HCRTR2, MCHR1, MCHR2 | POLB 3369/4885HPGD 2310/4885SMN1; SMN2 1477/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.